S 2276 Re-checks Congress.gov for new actions and updates the bill's status, and fills in any sponsors, committees, or related bills that are missing. It does not re-pull sponsors/cosponsors/committees/related — those rarely change — and it skips all work if nothing has changed upstream, so it's cheap to click.
To address patent thickets.
Summary
- Limits patent holders to asserting only one patent per "Patent Group" in infringement actions against makers and applicants of generic drugs and biosimilar biological products
- Prevents patent holders from bringing multiple infringement actions against the same generic drug or biosimilar company asserting different patents from the same Patent Group
- Defines a "Patent Group" as commonly owned patents that are connected through double patenting disclaimers
- Applies to generic drug and biosimilar applications submitted on or after the date of enactment
AI-generated plain-language summary of the bill text — neutral, and may be imperfect. See the full text below for the exact wording.
Sponsor (1)
- Sen. Welch, Peter [D-VT] (D-VT)
2 cosponsors
- Sen. Hawley, Josh [R-MO] (R-MO)
- Sen. Klobuchar, Amy [D-MN] (D-MN)
Money behind the sponsor
Top reported contributors to Peter Welch’s campaign committee (2024 cycle) — who funds the bill’s sponsor, not a claim about this bill. Data from FEC.
- NULL $8,600
- THE OLD MOUNTAIN COMPANY, INC. $3,300
- WEST FRONT STRATEGIES $2,500
- UCAR $2,300
- MINILEC SERVICE $2,000
Organizations whose employees gave the most — itemized individual contributions grouped by the donor’s reported employer (FEC Schedule A). Full finance for Peter Welch → · Outside spending →
Actions (2)
- Jul 15, 2025 Read twice and referred to the Committee on the Judiciary. · senate
- Jul 15, 2025 Introduced in Senate
Similar bills (6)
Bills with similar text or summary — includes reintroductions across Congresses. Ranked by semantic similarity of the bill text (computed locally); a neutral discovery aid, not a claim the bills are duplicates.
Text versions (1)
Bills are re-published as they move (Introduced → Reported → Engrossed → Enrolled …). Each stage below is a separate text; pick two to see what changed. Data from Congress.gov.
Full text
IN THE SENATE OF THE UNITED STATES
July 15, 2025
Mr. Welch (for himself, Mr. Hawley, and Ms. Klobuchar) introduced the following bill; which was read twice and referred to the Committee on the Judiciary
A BILL
To address patent thickets.
Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the “Eliminating Thickets to Increase Competition Act” or the “ETHIC Act”.
SEC. 2. ADDRESSING PATENT THICKETS.
(a) Limit on Number of Patents Per Patent Group That May Be Asserted in Action for Infringement.—Section 271(e) of title 35, United States Code, is amended by adding at the end the following:
“(7)(A) A person who brings an action for infringement of a patent under this section against a party described in subparagraph (B) may assert in the action not more than one patent per Patent Group.
“(B) A party described in this subparagraph is—
“(i) a person who—
“(I) submits an application for approval of a drug under subsection (b)(2) or (j) of section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355), or is a holder of such an approved application; or
“(II) submits an application for licensure of a biological product under section 351(k) of the Public Health Service Act (42 U.S.C. 262(k)), or is a holder of such a licensure; or
“(ii) a person making, using, selling, offering for sale, introducing or delivering into interstate commerce, or importing—
“(I) a drug approved pursuant to an application under subsection (b)(2) or (j) of section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355); or
“(II) a biological product licensed under section 351(k) of the Public Health Service Act (42 U.S.C. 262(k)).
“(C) A person who brings an action described in subparagraph (A) asserting a patent against a party may not bring any additional actions described in that subparagraph asserting a patent in the same Patent Group against that party.
“(D)(i) For purposes of this paragraph, the term ‘Patent Group’ means 2 or more commonly owned patents or applications that—
“(I) are identified on 1 or more disclaimers under section 253 to obviate obviousness-type double patenting of another commonly owned patent; or
“(II) are subject to 1 or more disclaimers under section 253 to obviate obviousness-type double patenting of another commonly owned patent.
“(ii) For purposes of clause (i)(I)—
“(I) each patent or application that identifies the same patent or application on a disclaimer under section 253 is part of the same Patent Group; and
“(II) each patent or application that is identified on a disclaimer under section 253 is part of the same Patent Group as the patent or application subject to the disclaimer.”.
(b) Applicability.—The amendment made by subsection (a) shall apply with respect to an application submitted under subsection (b)(2) or (j) of section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355) or section 351(k) of the Public Health Service Act (42 U.S.C. 262(k)) on or after the date of enactment of this Act. <all>
Comments